Hydroxychloroquine (All indications except Antiphospholipid Syndrom)

All congenital malformations (majors, minors, majors and minors, or unspecified)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13645
R52902
Bérard, 2021 Major congenital malformations 1st trimester nested case control unexposed (general population or NOS) Adjustment: Yes Indication HCQ: Any or not specified 1.15 [0.65;2.04] 16/103   23,975/230,972 23,991 103
ref
S13680
R53164
Howley - BDS study, 2021 Major birth defects early pregnancy case control unexposed (general population or NOS) Adjustment: No Indication HCQ: Rheumatic diseases as a whole (Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren's syndrome...) 0.62 [0.23;1.62] C 10/17   29,828/42,689 29,838 17
ref
S13681
R53172
Howley - NBDPS study, 2021 Major birth defects early pregnancy case control unexposed (general population or NOS) Adjustment: No Indication HCQ: Rheumatic diseases as a whole (Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren's syndrome...) 1.29 [0.43;3.93] C 14/18   31,454/43,064 31,468 18
ref
Total 3 studies 1.02 [0.65;1.61] 85,297 138
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bérard, 2021Bérard, 2021 1.15[0.65; 2.04]23,99110362%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Howley - BDS study, 2021Howley - BDS study, 2021 0.62[0.23; 1.62]29,8381722%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Howley - NBDPS study, 2021Howley - NBDPS study, 2021 1.29[0.43; 3.93]31,4681816%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 0% 1.02[0.65; 1.61]85,2971380.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0 case control studiescase control studies 1.02[0.65; 1.61]85,2971380%NABérard, 2021 Howley - BDS study, 2021 Howley - NBDPS study, 2021 3 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.02[0.65; 1.61]85,2971380%NABérard, 2021 Howley - BDS study, 2021 Howley - NBDPS study, 2021 3 Tags Adjustment   - No  - No 0.85[0.41; 1.76]61,306350%NAHowley - BDS study, 2021 Howley - NBDPS study, 2021 2   - Yes  - Yes 1.15[0.65; 2.04]23,991103 -NABérard, 2021 1 Indication HCQ   - Any or not specified  - Any or not specified 1.15[0.65; 2.04]23,991103 -NABérard, 2021 1   - Rheumatic diseases as a whole (Syst ...  - Rheumatic diseases as a whole (Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren's syndrome...) 0.85[0.41; 1.76]61,306350%NAHowley - BDS study, 2021 Howley - NBDPS study, 2021 2 All studiesAll studies 1.02[0.65; 1.61]85,2971380%NABérard, 2021 Howley - BDS study, 2021 Howley - NBDPS study, 2021 30.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.33[1.04; 1.69]203,3692,77516%NAChambers (Controls unexposed, disease free), 2022 Andersson (Controls unexposed, NOS), 2021 Bérard, 2021 Howley - BDS study, 2021 Howley - NBDPS study, 2021 Huybrechts (Controls unexposed, NOS), 2021 Diav-Citrin, 2013 Colvin, 2010 8 unexposed, sick controlsunexposed, sick controls 1.35[0.94; 1.93]1,1282,86322%NAChambers (Controls unexposed, sick), 2022 Reynolds, 2022 Huybrechts (Controls unexposed, sick), 2021 Howren, 2020 Leroux, 2015 Cooper (controls unexposed, sick), 2014 Clowse, 2006 Costedoat-Chalumeau, 2003 8 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.09[0.58; 2.06]654470%NAAndersson (Controls exposed to corticosteroides), 2021 Cooper (controls exposed to TNF-I), 2014 Langen, 2014 Vroom (controls exposed to sulfasalazine), 2009 40.510.01.0

Umbrella review (other published meta-analyses)

Published MATE95% CIn exposedkI2Control groupExposition period Duan (SLE indication)Duan (SLE indication) 0.53[0.14; 2.04]0%-unexposed, sickthroughout pregnancystudies4 Sperber (Autoimmune diseases)Sperber (Autoimmune diseases) 0.66[0.25; 1.75]0%-whatever (meta-analysis)during pregnancy (anytime or not specified)studies4 metaPregmetaPreg 1.02[0.65; 1.61]0%138--Bérard, 2021 Howley - BDS study, 2021 Howley - NBDPS study, 2021 30.510.01.0